FDA
-
-
-
-
-
-
-
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely
-
-
-
-
-
-
-
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
-
-
-
-
-
-
-
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
-
-
-
-
-
-
-
Abivax Announces a Change to the Composition of its Board of Directors
-
-
-
-
-
-
-
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
-
-
-
-
-
-
-
Abivax (ABVX) Provides Operational and Key Program Update
-
-
-
-
-
-
-
Abivax 2018 Financial Results and Operations Update
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

